^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    atirmociclib (PF-07220060)

    i
    Company:
    Pfizer
    Drug class:
    CDK4 inhibitor
    Related drugs:
    Apply
    Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (C4391001) (NCT04557449)
    Phase 1
    Pfizer
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    09/23/2020
    Primary completion :
    09/23/2026
    Completion :
    11/23/2027
    CDKN2A • CCND1 • CD4
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Xtandi (enzalutamide) • fulvestrant • letrozole • atirmociclib (PF-07220060) • midazolam hydrochloride
    Study of PF-07248144 in Advanced or Metastatic Solid Tumors (C4551001) (NCT04606446)
    Phase 1
    Pfizer
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    11/16/2020
    Primary completion :
    08/13/2025
    Completion :
    03/07/2027
    HER-2 • ER • CDKN2A
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    Ibrance (palbociclib) • fulvestrant • letrozole • atirmociclib (PF-07220060) • prifetrastat (PF-07248144)
    First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer (ReDiscover) (NCT05216432)
    Phase 1
    Relay Therapeutics, Inc.
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    12/08/2021
    Primary completion :
    12/31/2025
    Completion :
    08/31/2026
    HER-2 • PIK3CA • BRCA1 • BRCA2
    |
    HER-2 negative • PIK3CA mutation
    |
    Ibrance (palbociclib) • Piqray (alpelisib) • Kisqali (ribociclib) • fulvestrant • RLY-2608 • atirmociclib (PF-07220060)
    A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment (NCT06105632)
    Phase 3
    Pfizer
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    01/09/2024
    Primary completion :
    12/16/2025
    Completion :
    12/14/2028
    HER-2 • ER • PGR
    |
    HER-2 negative
    |
    everolimus • fulvestrant • exemestane • atirmociclib (PF-07220060)